Symptomtext
After the dose was administered, the daughter of the patient contacted the pharmacist and informed that the patient had received an unknown brand flu vaccine 3 days prior with no reported adverse event; Initial information was received on 09-Nov-2023 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 87 years old female patient who received INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] after the dose, the daughter of the patient contacted the pharmacist and informed that the patient had received an unknown brand flu vaccine 3 days prior with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 09-Nov-2023, the patient received a 0.7 ml dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot UT8111CA and expiry 30-06-24) (formulation, strength: unknown) that the patient had received an unknown brand flu vaccine 3 days prior with no reported adverse event (extra dose administered) via unknown route in unknown administration site for prophylactic vaccination (immunization). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.